<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2026.1760909</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A comparative dosimetric evaluation of two image-guided calibration strategies for multi-isocenter total body irradiation: integrated fan-beam CT&#x2013;based alignment versus sequential cone-beam CT&#x2013;guided localization</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name><surname>Gao</surname><given-names>Bo</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn003"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3060547/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name><surname>Hong</surname><given-names>Yaling</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="author-notes" rid="fn003"><sup>&#x2020;</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Yan</surname><given-names>Junjing</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Chen</surname><given-names>Xiwei</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Tan</surname><given-names>Suhua</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhu</surname><given-names>Yutao</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Liu</surname><given-names>Yan</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project-administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Yao</surname><given-names>Zhaojie</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project-administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Wu</surname><given-names>Lizhen</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project-administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Chen</surname><given-names>Haiyan</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>*</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1435572/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Lei</surname><given-names>Zhanquan</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>*</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label><institution>Department of Radiation Oncology, Fujian Children&#x2019;s Hospital (Fujian Branch of Shanghai Children&#x2019;s Medical Center), College of Clinical Medicine for Obstetrics &amp; Gynecology and Pediatrics, Fujian Medical University</institution>, <city>Fuzhou</city>, <state>Fujian</state>,&#xa0;<country country="cn">China</country></aff>
<aff id="aff2"><label>2</label><institution>Department of Radiation Oncology, Shanghai Children&#x2019;s Medical Center Affiliated to Shanghai Jiaotong University School of Medicine Institute</institution>, <city>Shanghai</city>,&#xa0;<country country="cn">China</country></aff>
<aff id="aff3"><label>3</label><institution>Hunan Provincial Hospital of Integrated Traditional Chinese and Western Medicine</institution>, <city>Changsha</city>, <state>Hunan</state>,&#xa0;<country country="cn">China</country></aff>
<author-notes>
<corresp id="c001"><label>*</label>Correspondence: Haiyan Chen, <email xlink:href="mailto:Chenhaiyan1220@163.com">Chenhaiyan1220@163.com</email>; Zhanquan Lei, <email xlink:href="mailto:244902263@qq.com">244902263@qq.com</email></corresp>
<fn fn-type="equal" id="fn003">
<label>&#x2020;</label>
<p>These authors have contributed equally to this work</p></fn>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-03-04">
<day>04</day>
<month>03</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2026</year>
</pub-date>
<volume>16</volume>
<elocation-id>1760909</elocation-id>
<history>
<date date-type="received">
<day>04</day>
<month>12</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>09</day>
<month>02</month>
<year>2026</year>
</date>
<date date-type="rev-recd">
<day>27</day>
<month>01</month>
<year>2026</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2026 Gao, Hong, Yan, Chen, Tan, Zhu, Liu, Yao, Wu, Chen and Lei.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Gao, Hong, Yan, Chen, Tan, Zhu, Liu, Yao, Wu, Chen and Lei</copyright-holder>
<license>
<ali:license_ref start_date="2026-03-04">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Image-guided radiotherapy (IGRT) is key to making sure the radiation dose is accurate when treating kids with multi-isocenter total body irradiation (TBI). Ensuring dose accuracy in pediatric multi-isocenter TBI. Shanghai Children&#x2019;s Medical Center employed low-dose fan-beam CT (FBCT) for integrated multi-isocenter calibration, whereas Fujian Children&#x2019;s Hospital used cone-beam CT (CBCT) for sequential isocenter alignment.</p>
</sec>
<sec>
<title>Objective</title>
<p>To evaluate FBCT versus CBCT guidance effects on target coverage and organ doses across two regimens: 12 Gy in 6 fractions and 3 Gy in 1 fraction.</p>
</sec>
<sec>
<title>Methods</title>
<p>Retrospective analysis of 34 pediatric TBI patients (21 FBCT, 13 CBCT) treated with identical field setups (three upper-body isocenters; two/three lower-body isocenters; junction at upper femur third). Pre-treatment FBCT/CBCT images were registered to planning CTs; doses recalculated using original plans. Metrics: PTV V90%, V100%, V110%, mean doses; homogeneity index (HI); conformity index (CI); mean lung and kidney doses.</p>
</sec>
<sec>
<title>Results</title>
<p>In the 12 Gy group, FBCT guidance improved PTV coverage: V<sub>90%</sub> increased from 96.11% to 97.14%, V<sub>100%</sub> from 90.40% to 92.81%, and V<sub>110%</sub> decreased from 20.73% to 16.67% (all P &lt; 0.01). HI decreased from 0.25 to 0.16, CI increased from 0.77 to 0.89, and mean PTV dose rose from 12.33 to 12.57 Gy (all P &lt; 0.01). Mean lung dose fell from 8.61 to 8.47 Gy, and mean kidney dose from 8.24 to 8.10 Gy (both P &lt; 0.01). In the 3 Gy group, FBCT guidance also improved PTV coverage: V<sub>90%</sub> increased from 96.32% to 97.82%, V<sub>100%</sub> from 91.44% to 93.97%, and V<sub>110%</sub> decreased from 17.43% to 13.72% (all P &lt; 0.01). HI decreased from 0.21 to 0.13, CI increased from 0.77 to 0.87, and mean PTV dose rose from 3.08 to 3.12 Gy (all P &lt; 0.01). Mean lung dose decreased from 2.34 to 2.25 Gy, and mean kidney dose from 2.09 to 2.06 Gy (both P &lt; 0.01).</p>
</sec>
<sec>
<title>Conclusion</title>
<p>FBCT guidance gave better target dose conformity and homogeneity, and lower lung doses, than CBCT guidance&#x2014;both for the 12 Gy myeloablative regimen and the 3 Gy low-dose regimen. These results suggest that FBCT guidance is a better option for image-guided total body irradiation in children.</p>
</sec>
</abstract>
<kwd-group>
<kwd>children</kwd>
<kwd>cone-beam CT</kwd>
<kwd>dosimetry</kwd>
<kwd>fan-beam CT</kwd>
<kwd>image guidance</kwd>
<kwd>total body irradiation</kwd>
</kwd-group>
<funding-group>
<award-group id="gs1">
<funding-source id="sp1">
<institution-wrap>
<institution>Natural Science Foundation of Fujian Province</institution>
<institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100003392</institution-id>
</institution-wrap>
</funding-source>
<award-id rid="sp1">2023J011299</award-id>
</award-group>
<funding-statement>The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the Natural Science Foundation of Fujian Province (Grant numbers: 2023J011299 and 2023J011305).</funding-statement>
</funding-group>
<counts>
<fig-count count="2"/>
<table-count count="3"/>
<equation-count count="1"/>
<ref-count count="23"/>
<page-count count="7"/>
<word-count count="3271"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Radiation Oncology</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>Total body irradiation (TBI) is a standard part of the treatment before hematopoietic stem cell transplantation [cf (<xref ref-type="bibr" rid="B1">1</xref>).]. It is commonly used for children with acute leukemia or aplastic anemia. TBI works by killing remaining cancer or abnormal blood cells and weakening the patient&#x2019;s immune system to help the new stem cells take hold [cf (<xref ref-type="bibr" rid="B2">2</xref>).]. In traditional TBI (also called 2D-TBI), large radiation fields are used&#x2014;front-to-back or side-to-side&#x2014;at a long distance from the machine to the skin (usually over 2 meters). Lead blocks are placed in the beam to protect the lungs and kidneys, lowering the risk of lung or kidney damage [cf (<xref ref-type="bibr" rid="B3">3</xref>).]. Newer methods like helical tomotherapy (HT) [cf (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>).], volumetric modulated arc therapy (VMAT) [cf (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>).], and fixed-angle intensity-modulated radiotherapy (IMRT) can also deliver TBI [cf (<xref ref-type="bibr" rid="B8">8</xref>).]. IMRT shapes the radiation dose more precisely, reducing dose to sensitive organs like the lungs and kidneys while still giving full dose to the target. This helps lower side effects without reducing treatment effectiveness&#x2014;and may improve long-term outcomes [cf (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>).].</p>
<p>Linear accelerators have a limited radiation field size. To deliver TBI with VMAT, multiple isocenters are needed&#x2014;usually three for the upper body (head, chest, and abdomen) and two or three for the lower body, with the junction at the top of the femur [cf (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>).]. This method covers the whole body but makes it hard to match doses smoothly at the junctions. Even small setup errors can lead to areas in the target that get too little or too much radiation [cf (<xref ref-type="bibr" rid="B10">10</xref>).].</p>
<p>Image-guided radiotherapy (IGRT) is now standard for TBI to correct daily positioning differences. Most centers use kilovoltage cone-beam CT (CBCT)[cf (<xref ref-type="bibr" rid="B11">11</xref>).]; low-dose fan-beam CT (FBCT) is a newer option [cf (<xref ref-type="bibr" rid="B12">12</xref>).]. With CBCT, you need a separate scan and alignment for each isocenter. That takes more time and makes it hard to keep all isocenters lined up correctly relative to each other. FBCT, on the other hand, takes one low-dose scan that covers the full length of the body&#x2014;just like the plan CT (pCT) [cf (<xref ref-type="bibr" rid="B12">12</xref>).]. One alignment to the original pCT then tells the system how to move the treatment couch to line up all isocenters at once. This gives real whole-body correction.</p>
<p>Both FBCT and CBCT are used in children receiving TBI, but no study has directly compared how they affect radiation dose&#x2014;especially to the target, lungs, and kidneys. This study compares two real-world approaches: the FBCT method used at Shanghai Children&#x2019;s Medical Center, which aligns all isocenters in one step, and the CBCT method used at Fujian Children&#x2019;s Hospital, which adjusts each isocenter separately. We test both methods for two common TBI schedules: 12 Gy in fractions (myeloablative) and 3 Gy in 1 fractions. The main outcomes are how much of the target receives at least 95% of the prescribed dose, and the average dose to both lungs and both kidneys. Results will help teams choose the best image-guidance method for children having TBI.</p>
</sec>
<sec id="s2">
<label>2</label>
<title>Patients and methods</title>
<sec id="s2_1">
<label>2.1</label>
<title>Patient information</title>
<p>We included 34 children who received total body irradiation (TBI) at Shanghai Children&#x2019;s Medical Center or Fujian Children&#x2019;s Hospital between January 2023 and August 2025. The children were divided into two groups: 18 received 12 Gy in 6 fractions (12 from Shanghai and 6 from Fujian), and 16 received 3 Gy in 1 fraction (9 from Shanghai and 7 from Fujian). Inclusion criteria were age 3 to 18 years, diagnosis of ALL, AML, AA, or other conditions requiring TBI before transplant, completion of the full treatment course, and availability of complete image-guided radiation therapy (IGRT) images and dose data. We excluded children with major setup errors, poor image quality, or who withdrew from treatment. <xref ref-type="table" rid="T1"><bold>Table&#xa0;1</bold></xref> shows the two groups did not differ significantly in sex, age, radiotherapy technique, diagnosis, or other factors (all P &gt; 0.05).</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Baseline characteristics of the patients V<sub>90%</sub> represents the percentage of the total target volume in the area where more than 90% of the prescribed dose is administered, and V<sub>100%</sub>, V<sub>110%</sub> similarly, Dmax refers to the highest dose in the target.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" colspan="2" align="center">Characteristic</th>
<th valign="middle" align="center">FBCT group n = 21</th>
<th valign="middle" align="center">CBCT group n = 3</th>
<th valign="middle" align="center">P</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" colspan="2" align="left">Age (years)</td>
<td valign="middle" align="left">12.8</td>
<td valign="middle" align="left">12.4</td>
<td valign="middle" align="left">0.72</td>
</tr>
<tr>
<td valign="middle" colspan="2" align="left">Male(n, %)</td>
<td valign="middle" align="left">12 (57.1%)</td>
<td valign="middle" align="left">8 (61.5%)</td>
<td valign="middle" align="left">0.13</td>
</tr>
<tr>
<td valign="middle" colspan="2" align="left">Technology</td>
<td valign="middle" align="left">VMAT</td>
<td valign="middle" align="left">VMAT</td>
<td valign="middle" align="left">&#x2014;</td>
</tr>
<tr>
<td valign="middle" colspan="2" align="left">Diagnosis: ALL/AML</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">&#x2014;</td>
</tr>
<tr>
<td valign="middle" colspan="2" align="left">Diagnosis: SAA</td>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">7</td>
<td valign="middle" align="left">&#x2014;</td>
</tr>
<tr>
<td valign="middle" rowspan="2" align="left">Mean V<sub>90%</sub>(%)</td>
<td valign="middle" rowspan="2" align="left">12Gy</td>
<td valign="middle" align="left">98.15</td>
<td valign="middle" align="left">98.12</td>
<td valign="middle" align="left">0.49</td>
</tr>
<tr>
<td valign="middle" align="left">98.44</td>
<td valign="middle" align="left">98.43</td>
<td valign="middle" align="left">0.44</td>
</tr>
<tr>
<td valign="middle" rowspan="2" align="left">Mean V<sub>100%</sub>(%)</td>
<td valign="middle" rowspan="2" align="left">6Gy</td>
<td valign="middle" align="left">93.34</td>
<td valign="middle" align="left">93.20</td>
<td valign="middle" align="left">0.37</td>
</tr>
<tr>
<td valign="middle" align="left">94.68</td>
<td valign="middle" align="left">94.77</td>
<td valign="middle" align="left">0.32</td>
</tr>
<tr>
<td valign="middle" rowspan="2" align="left">Mean V<sub>110%</sub>(%)</td>
<td valign="middle" rowspan="2" align="left">12Gy</td>
<td valign="middle" align="left">7.37</td>
<td valign="middle" align="left">7.25</td>
<td valign="middle" align="left">0.37</td>
</tr>
<tr>
<td valign="middle" align="left">5.82</td>
<td valign="middle" align="left">5.70</td>
<td valign="middle" align="left">0.25</td>
</tr>
<tr>
<td valign="middle" rowspan="2" align="left">PTV mean dose</td>
<td valign="middle" rowspan="2" align="left">6Gy</td>
<td valign="middle" align="left">12.55</td>
<td valign="middle" align="left">12.52</td>
<td valign="middle" align="left">0.69</td>
</tr>
<tr>
<td valign="middle" align="left">3.09</td>
<td valign="middle" align="left">3.08</td>
<td valign="middle" align="left">0.75</td>
</tr>
<tr>
<td valign="middle" rowspan="2" align="left">Lungs mean dose</td>
<td valign="middle" rowspan="2" align="left">12Gy</td>
<td valign="middle" align="left">7.89</td>
<td valign="middle" align="left">7.91</td>
<td valign="middle" align="left">0.28</td>
</tr>
<tr>
<td valign="middle" align="left">2.05</td>
<td valign="middle" align="left">2.09</td>
<td valign="middle" align="left">0.35</td>
</tr>
<tr>
<td valign="middle" rowspan="2" align="left">Kidneys mean dose</td>
<td valign="middle" rowspan="2" align="left">6Gy</td>
<td valign="middle" align="left">7.68</td>
<td valign="middle" align="left">7.69</td>
<td valign="middle" align="left">0.31</td>
</tr>
<tr>
<td valign="middle" align="left">1.95</td>
<td valign="middle" align="left">1.96</td>
<td valign="middle" align="left">0.40</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2_2">
<label>2.2</label>
<title>Radiotherapy planning design method (consistent in two centers)</title>
<p>Both centers are partner hospitals in a shared clinical research program. All TBI plans were created and reviewed by the same team of medical physicists and radiation oncologists, ensuring consistent planning and quality control across sites. Shanghai Children&#x2019;s Medical Center used uTPS (United Imaging Healthcare, version 1520); Fujian Children&#x2019;s Hospital used Varian Eclipse (Siemens Healthineers, version 15.5), as shown in <xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1</bold></xref>. For VMAT delivery, the upper body used three isocenters (two full 360&#xb0; arcs for the head, three for the chest, and three for the abdomen), and the lower body used two to three isocenters (two arcs each for the thighs, knees, and calves). The field junction was placed at the upper third of the femur. Target volumes followed standard clinical contouring guidelines and are illustrated in <xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2</bold></xref>. Plan acceptance criteria were: PTV V90% &gt; 95%, PTV V100% &gt; 90%, and PTV Dmax &lt; 120% of the prescription dose. Here, V90% and V100% refer to the percentage of PTV volume receiving at least 90% or 100% of the prescription dose. Organ-at-risk limits were: mean lung dose &lt; 66.7%, mean kidney dose &lt; 83.3%, and lens dose &lt; 50% of the prescription dose. The maximum dose rate was 100 MU/min; the average dose rate to the lungs was about 10 cGy/min. While some studies suggest that lower dose rates may reduce the risk of radiation pneumonitis [cf (<xref ref-type="bibr" rid="B13">13</xref>).], none of the 47 patients developed acute radiation pneumonitis. This observation was not part of the study&#x2019;s primary objectives and is not discussed further.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Schematic diagram of the field arrangement for radiotherapy planning.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-16-1760909-g001.tif">
<alt-text content-type="machine-generated">The image illustrates the VMAT beam arrangement for radiotherapy on both the upper and lower body. The upper body consists of 8 full arcs from 3 isocenters, while the lower body consists of 6 full arcs from 3 isocenters.</alt-text>
</graphic></fig>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>TBI target area. The red line segment in the figure encloses the PTV of the TBI target area, and the outermost yellow line represents the body surface contour. The outer contour of the body surface is indented by 3mm, and the lens and the area 3mm outside the outer contour of the lens are removed, as well as the area 5mm inside the outer contour of the lungs and the area 5mm inside the outer contour of the kidneys. The resulting area is the PTV of the TBI target area.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-16-1760909-g002.tif">
<alt-text content-type="machine-generated">The image shows the target volume coverage for total body irradiation on both the upper and lower body. The target area is highlighted in red, encompassing the peripheral regions of both lungs and both kidneys.</alt-text>
</graphic></fig>
<p>As shown in <xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2</bold></xref>, the area surrounded by the red line is the TBI target area (irradiation range), namely the PTV, which is defined as:</p>
<disp-formula>
<mml:math display="block" id="M1"><mml:mrow><mml:mtext>PTV</mml:mtext><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mtext>Body</mml:mtext></mml:mrow><mml:mrow><mml:mtext>i</mml:mtext><mml:mo>_</mml:mo><mml:mn>3</mml:mn><mml:mtext>mm</mml:mtext></mml:mrow></mml:msub><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mrow><mml:mtext>Lungs</mml:mtext></mml:mrow><mml:mrow><mml:mtext>i</mml:mtext><mml:mo>_</mml:mo><mml:mn>5</mml:mn><mml:mtext>mm</mml:mtext></mml:mrow></mml:msub><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mrow><mml:mtext>Kidneys</mml:mtext></mml:mrow><mml:mrow><mml:mtext>i</mml:mtext><mml:mo>_</mml:mo><mml:mn>5</mml:mn><mml:mtext>mm</mml:mtext></mml:mrow></mml:msub><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mrow><mml:mtext>Lens</mml:mtext></mml:mrow><mml:mrow><mml:mtext>o</mml:mtext><mml:mo>_</mml:mo><mml:mn>3</mml:mn><mml:mtext>mm</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:math>
</disp-formula>
<p>Here, Body<sub>i_3mm</sub> represents the area with a 3mm inward contraction from the outer contour of the body surface, Lungs<sub>i_5mm</sub> represents the area with a 5mm inward contraction from the outer contour of both lungs, Kidneys<sub>i_5mm</sub> represents the area with a 5mm inward contraction from the outer contour of both kidneys, and Lens<sub>o_3mm</sub> represents the area with a 3mm outward expansion from the outer contour of the lens.</p>
</sec>
<sec id="s2_3">
<label>2.3</label>
<title>TBI treatment and IGRT methods</title>
<p>The patient was immobilized using a thermoplastic head mask and a vacuum cushion, with auxiliary skin markings placed on the body to facilitate reproducible setup. Treatment was delivered in two distinct positional configurations: head-first supine (HFS) for the upper-body target volume, followed by feet-first supine (FFS) for the lower-body target volume. Prior to each treatment fraction, volumetric image guidance was performed. All image registrations were independently reviewed and approved by a board-certified radiation oncologist; treatment proceeded only after formal sign-off. The institutional image-guidance protocols are summarized below:</p>
<p>Shanghai Children&#x2019;s Medical Center: Integrated multi-isocenter FBCT calibration. Equipment: uRT-linac 506c (United Imaging Healthcare) &#x2014; A device integrating FBCT and a linear accelerator, 1-meter longitudinal FBCT volumes in a single continuous scan.</p>
<p>Workflow: (1) A single low-dose FBCT scan covering the entire treatment region is acquired immediately before treatment; (2) the FBCT is rigidly registered to the pCT as a unified volume; (3) the system computes translational and rotational offsets for all planned isocenters simultaneously, preserving their relative spatial relationships; (4) the couch is adjusted once&#x2014;based on the composite correction vector&#x2014;to align all isocenters globally; (5) no additional per-isocenter verification scans are performed.</p>
<p>Fujian Children&#x2019;s Hospital: Sequential single-isocenter CBCT calibration. Equipment: Varian TrueBeam (Varian Medical Systems, now part of Siemens Healthineers) &#x2014; equipped with an on-board CBCT.</p>
<p>Workflow: (1) A localized CBCT scan is acquired at each individual isocenter location; (2) each CBCT is rigidly registered to its corresponding anatomical region in the pCT; (3) the couch is repositioned separately for each isocenter based on its unique registration result; (4) inter-isocenter geometric consistency is not enforced during registration or couch movement&#x2014;each is treated as an independent setup.</p>
</sec>
<sec id="s2_4">
<label>2.4</label>
<title>Dose recalculation and evaluation</title>
<p>The patients at Shanghai Children&#x2019;s Medical Center used their current IGRT images to locate the beam isocenter on the FBCT. Subsequently, the beam was transferred to the FBCT for dose recalculation to estimate the actual radiation dose distribution received by the patient at this treatment stage. At Fujian Children&#x2019;s Hospital, the Varian Velocity software (version 4.1) was used to generate a registered CT (rCT) through deformable registration. First, the pCT and CBCT were rigidly aligned. Then, Velocity performed deformable registration between them to compute a deformation vector field. Using this field, the PTV and organs at risk were mapped from the pCT onto the CBCT. A senior radiation oncologist reviewed and confirmed the accuracy of these contours on the CBCT. Next, the inverse of the deformation field was applied to the pCT to produce the rCT. Finally, dose was recalculated on the rCT to estimate the actual dose distribution for that session.</p>
<p>Evaluation metrics included: PTV: V<sub>90%</sub> (percentage of PTV receiving &#x2265;90% of the prescribed dose), V<sub>100%</sub>, V<sub>110%</sub>, PTV mean dose, homogeneity index HI (per ICRU Report 83; lower values indicate better uniformity), and conformity index CI (per Paddick definition; values closer to 1 indicate better conformity). Organs at risk: mean lung dose and mean kidney dose. Statistical analysis was done using SPSS 26.0. Continuous variables are reported as mean &#xb1; standard deviation. Group comparisons used the Wilcoxon rank sum test. A p-value &lt; 0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<label>3</label>
<title>Results</title>
<p>As shown in <xref ref-type="table" rid="T1"><bold>Table&#xa0;1</bold></xref>, the two groups were well balanced with respect to age (12.8 vs 12.4 years), sex distribution (57.1% vs 61.5% male), diagnosis (ALL/AML: 12 vs 6; AA: 9 vs 7), radiotherapy technique, and prescribed dose (P &gt; 0.05). No significant differences were found in PTV dose metrics (V<sub>90%</sub>, V<sub>100%</sub>, V<sub>110%</sub>, mean dose) or mean doses to both lungs and both kidneys.</p>
<p>As shown in <xref ref-type="table" rid="T2"><bold>Table&#xa0;2</bold></xref>, in the 12 Gy/6F regimen, the FBCT-guided group achieved superior target coverage and organ sparing compared with the CBCT-guided group: V<sub>90%</sub> was 97.14% vs 96.11% (P &lt; 0.01); V<sub>100%</sub> was 92.81% vs 90.40% (P &lt; 0.01); HI was 0.16 vs 0.25; CI was 0.89 vs 0.77. Mean lung dose was reduced by 0.14 Gy (8.47 vs 8.61 Gy), and mean kidney dose was reduced by 0.14 Gy (8.10 vs 8.24 Gy); all differences were statistically significant (P &lt; 0.05).</p>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Dosimetric results for the 12 Gy in 6 fractions regimen.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left"/>
<th valign="middle" colspan="6" align="center">PTV dose</th>
<th valign="middle" rowspan="2" align="left">Lungs mean dose (Gy)</th>
<th valign="middle" rowspan="2" align="left">Kidneys mean dose (Gy)</th>
</tr>
<tr>
<th valign="middle" align="left">Parameter</th>
<th valign="middle" align="left">V90% (%)</th>
<th valign="middle" align="left">V100% (%)</th>
<th valign="middle" align="left">V110% (%)</th>
<th valign="middle" align="left">mean dose(Gy)</th>
<th valign="middle" align="left">HI</th>
<th valign="middle" align="left">CI</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">FBCT group</td>
<td valign="middle" align="left">97.14 &#xb1; 0.50</td>
<td valign="middle" align="left">92.81 &#xb1; 1.15</td>
<td valign="middle" align="left">16.67 &#xb1; 2.87</td>
<td valign="middle" align="left">12.57 &#xb1; 0.25</td>
<td valign="middle" align="left">0.16 &#xb1; 0.03</td>
<td valign="middle" align="left">0.89 &#xb1; 0.03</td>
<td valign="middle" align="left">8.47 &#xb1; 0.28</td>
<td valign="middle" align="left">8.10 &#xb1; 0.22</td>
</tr>
<tr>
<td valign="middle" align="left">CBCT group</td>
<td valign="middle" align="left">96.11 &#xb1; 1.20</td>
<td valign="middle" align="left">90.40 &#xb1; 3.80</td>
<td valign="middle" align="left">20.73 &#xb1; 4.21</td>
<td valign="middle" align="left">12.33 &#xb1; 0.44</td>
<td valign="middle" align="left">0.25 &#xb1; 0.03</td>
<td valign="middle" align="left">0.77 &#xb1; 0.05</td>
<td valign="middle" align="left">8.61 &#xb1; 0.34</td>
<td valign="middle" align="left">8.24 &#xb1; 0.26</td>
</tr>
<tr>
<td valign="middle" align="left">P</td>
<td valign="middle" align="left">&lt;0.01</td>
<td valign="middle" align="left">&lt;0.01</td>
<td valign="middle" align="left">&lt;0.01</td>
<td valign="middle" align="left">&lt;0.01</td>
<td valign="middle" align="left">&lt;0.01</td>
<td valign="middle" align="left">&lt;0.01</td>
<td valign="middle" align="left">&lt;0.01</td>
<td valign="middle" align="left">&lt;0.01</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>As shown in <xref ref-type="table" rid="T3"><bold>Table&#xa0;3</bold></xref>, the 3 Gy/1F regimen showed consistent improvements: V<sub>100%</sub> was 93.97% vs 91.44% (P &lt; 0.05); HI was 0.13 vs 0.21; CI was 0.87 vs 0.77; mean lung dose was 2.25 vs 2.34 Gy (P &lt; 0.05); mean kidney dose was 2.09 vs 2.11 Gy (P &lt; 0.05). Importantly, V<sub>110%</sub> was lower in the FBCT group for both regimens, indicating a more homogeneous dose distribution and reduced risk of local overdosing. All reported dosimetric differences were statistically significant (P &lt; 0.05).</p>
<table-wrap id="T3" position="float">
<label>Table&#xa0;3</label>
<caption>
<p>Dosimetric results for the 3 Gy in 1 fractions regimen.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left"/>
<th valign="middle" colspan="6" align="center">PTV dose</th>
<th valign="middle" rowspan="2" align="left">Lungs mean dose (Gy)</th>
<th valign="middle" rowspan="2" align="left">Kidneys mean dose (Gy)</th>
</tr>
<tr>
<th valign="middle" align="left">Parameter</th>
<th valign="middle" align="left">V90% (%)</th>
<th valign="middle" align="left">V100% (%)</th>
<th valign="middle" align="left">V110% (%)</th>
<th valign="middle" align="left">mean dose(Gy)</th>
<th valign="middle" align="left">HI</th>
<th valign="middle" align="left">CI</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">FBCT group</td>
<td valign="middle" align="left">97.82 &#xb1; 0.44</td>
<td valign="middle" align="left">93.97 &#xb1; 0.93</td>
<td valign="middle" align="left">13.72 &#xb1; 1.96</td>
<td valign="middle" align="left">3.12 &#xb1; 0.11</td>
<td valign="middle" align="left">0.13 &#xb1; 0.02</td>
<td valign="middle" align="left">0.87 &#xb1; 0.04</td>
<td valign="middle" align="left">2.25 &#xb1; 0.12</td>
<td valign="middle" align="left">2.09 &#xb1; 0.06</td>
</tr>
<tr>
<td valign="middle" align="left">CBCT group</td>
<td valign="middle" align="left">96.32 &#xb1; 2.63</td>
<td valign="middle" align="left">91.44 &#xb1; 3.10</td>
<td valign="middle" align="left">17.43 &#xb1; 3.50</td>
<td valign="middle" align="left">3.08 &#xb1; 0.12</td>
<td valign="middle" align="left">0.21 &#xb1; 0.03</td>
<td valign="middle" align="left">0.77 &#xb1; 0.06</td>
<td valign="middle" align="left">2.34 &#xb1; 0.15</td>
<td valign="middle" align="left">2.11 &#xb1; 0.05</td>
</tr>
<tr>
<td valign="middle" align="left">P</td>
<td valign="middle" align="left">&lt;0.01</td>
<td valign="middle" align="left">&lt;0.01</td>
<td valign="middle" align="left">&lt;0.01</td>
<td valign="middle" align="left">&lt;0.01</td>
<td valign="middle" align="left">&lt;0.01</td>
<td valign="middle" align="left">&lt;0.01</td>
<td valign="middle" align="left">&lt;0.01</td>
<td valign="middle" align="left">&lt;0.01</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s4" sec-type="discussion">
<label>4</label>
<title>Discussion</title>
<p>This is the first study to directly compare FBCT-based multi-center integrated image guidance with CBCT-based center-specific calibration for pediatric total body irradiation (TBI), using both the myeloablative (12 Gy/6F) and low-dose (3 Gy/1F) regimens. FBCT guidance consistently improved target coverage, dose homogeneity, and lung protection &#x2014; regardless of the regimen used. The average difference between measured and planned doses was under 2% for both guidance methods (12 Gy group: Fujian protocol &#x2014; 12.57 Gy vs. 12.52 Gy). In contrast, Patel et&#xa0;al. [cf (<xref ref-type="bibr" rid="B14">14</xref>).] reported a ~4% discrepancy, Kawa-Iwanicka et&#xa0;al. [cf (<xref ref-type="bibr" rid="B15">15</xref>).] reported &gt;7%, and Sarkar et&#xa0;al. [cf (<xref ref-type="bibr" rid="B16">16</xref>).] found a 10.4% deviation when using extended SSD for TBI. These findings confirm that both CBCT and FBCT guidance achieve clinically acceptable dose accuracy in pediatric TBI.</p>
<p>The main challenge in TBI is maintaining uniform dose across the entire body. Linear accelerator fields are typically under 40 cm, so full-body coverage requires multiple isocenters. Bo Gao et&#xa0;al. [cf (<xref ref-type="bibr" rid="B10">10</xref>).] and Qilin Li et&#xa0;al. [cf (<xref ref-type="bibr" rid="B17">17</xref>).] reported cold spots and hot spots at beam junctions due to setup errors. CBCT-based IGRT registers only one isocenter at a time. It does not account for how other isocenters move relative to it. For example, if the chest isocenter moves 1 mm forward and the abdomen isocenter moves 1 mm backward, the junction shifts by 2 mm. This causes dose gradients to deviate from the plan, reducing V<sub>90%</sub> and increasing V<sub>110%</sub>. Yongqiang Zhou et&#xa0;al. [cf (<xref ref-type="bibr" rid="B18">18</xref>).] also found underdosing and overdosing at junctions in multi-isocenter treatments. FBCT (e.g., United Imaging uCT-ART) captures a single low-dose image up to 1 m long [cf (<xref ref-type="bibr" rid="B19">19</xref>).], this image matches the pCT geometry. The system uses this match to compute offsets for all isocenters at once. Then it moves the treatment couch as one unit. This prevents misalignment between isocenters.</p>
<p>The mean lung dose is an independent predictor of radiation pneumonitis. Wong et&#xa0;al. [cf (<xref ref-type="bibr" rid="B20">20</xref>).] found that controlling the mean lung dose below 8&#x2013;10 Gy significantly reduces the incidence of radiation pneumonitis. Guo et&#xa0;al. [cf (<xref ref-type="bibr" rid="B21">21</xref>).] showed that intensity-modulated radiotherapy (IMRT) techniques such as VMAT-TBI reduce the mean lung dose from 10.8 &#xb1; 0.7 Gy to 9.4 &#xb1; 0.8 Gy. In this study, lung doses estimated using IGRT imaging were 8.61 Gy for the CBCT group and 8.47 Gy for the FBCT group, a reduction of 0.14 Gy. Lower lung doses likely offer better protection for the lungs. Even with a 3 Gy single-fraction regimen, the FBCT group had a mean lung dose 0.09 Gy lower than the CBCT group, suggesting FBCT may provide long-term benefits by reducing late lung function damage.For renal tissue, Kal et&#xa0;al. [cf (<xref ref-type="bibr" rid="B22">22</xref>).] proposed a biological effective dose (BED) tolerance threshold of approximately 16 Gy, equivalent to a mean dose limit of 10.56 Gy for the 12 Gy/6F fractionation schedule. In this study, the maximum mean renal dose was 8.61 &#xb1; 0.34 Gy in the 12 Gy/6F CBCT group, which remains below the reported limit. Shahid et&#xa0;al. [cf (<xref ref-type="bibr" rid="B23">23</xref>).] reported mean left and right renal doses of 9.17 Gy and 8.05 Gy when using VMAT for total bone marrow irradiation, values comparable to those in this study. FBCT also showed a dose advantage for the kidneys. Beyond dose benefits, FBCT has clear advantages in operational efficiency and imaging dose. A single FBCT scan takes less than 60 seconds to complete. This is clinically important for pediatric patients, especially those requiring sedation or with difficulty cooperating, because it shortens treatment time and reduces additional radiation exposure.</p>
<p>This study is a retrospective analysis with a limited sample size, and dynamic factors such as respiratory motion were not included. Additionally, the study primarily evaluated dosimetric differences between FBCT- and CBCT-guided total body irradiation, demonstrating the dose advantages of FBCT&#x2019;s integrated long-target imaging guidance; however, it did not propose solutions to mitigate these dosimetric differences. Finally, the clinical adoption of FBCT remains constrained by limited equipment availability, as the technique is currently implemented in only a few radiotherapy centers worldwide.</p>
</sec>
<sec id="s5" sec-type="conclusions">
<label>5</label>
<title>Conclusion</title>
<p>FBCT-enabled multi-isocenter integrated image guidance demonstrates clear advantages over traditional sequential isocenter setup with CBCT in pediatric total body irradiation (TBI). This approach enhances target dose coverage and uniformity across prescription regimens while reducing mean lung dose, representing a promising strategy for precise and safe TBI delivery.</p>
</sec>
</body>
<back>
<sec id="s6" sec-type="data-availability">
<title>Data availability statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec>
<sec id="s7" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>The studies involving humans were approved by Ethics Review Committee of Fujian Children&#x2019;s Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required from the participants or theparticipants&#x2019; legal guardians/next of kin in accordance with the national legislation and institutional requirements.</p></sec>
<sec id="s8" sec-type="author-contributions">
<title>Author contributions</title>
<p>BG: Conceptualization, Writing &#x2013; original draft. YH: Formal analysis, Writing &#x2013; review &amp; editing. JY: Formal analysis, Writing &#x2013; review &amp; editing. XC: Formal analysis, Writing &#x2013; review &amp; editing. ST: Formal analysis, Investigation, Writing &#x2013; original draft. YZ: Formal analysis, Writing &#x2013; original draft. YL: Project administration, Writing&#xa0;&#x2013; original draft. ZY: Project administration, Writing &#x2013; original draft. LW: Project administration, Writing &#x2013; original draft. HC: Funding acquisition, Writing &#x2013; original draft. ZL: Funding acquisition, Writing &#x2013; original draft.</p></sec>
<sec id="s10" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec>
<sec id="s11" sec-type="ai-statement">
<title>Generative AI statement</title>
<p>The author(s) declared that generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec>
<sec id="s12" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sabloff</surname> <given-names>M</given-names></name>
<name><surname>Tisseverasinghe</surname> <given-names>S</given-names></name>
<name><surname>Babadagli</surname> <given-names>ME</given-names></name>
<name><surname>Samant</surname> <given-names>R</given-names></name>
</person-group>. 
<article-title>Total body irradiation for hematopoietic stem cell transplantation: what can we agree on</article-title>? <source>Curr Oncol</source>. (<year>2021</year>) <volume>28</volume>:<page-range>903&#x2013;17</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/curroncol28010089</pub-id>, PMID: <pub-id pub-id-type="pmid">33617507</pub-id>
</mixed-citation>
</ref>
<ref id="B2">
<label>2</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Simiele</surname> <given-names>E</given-names></name>
<name><surname>Dandapani</surname> <given-names>S</given-names></name>
<name><surname>Han</surname> <given-names>C</given-names></name>
<name><surname>Wong</surname> <given-names>J</given-names></name>
<name><surname>Hiniker</surname> <given-names>SM</given-names></name>
<name><surname>Kovalchuk</surname> <given-names>N</given-names></name>
</person-group>. 
<article-title>Radiation as an immune modulator: where we are with modern total body irradiation</article-title>. <source>Semin Radiat Oncol</source>. (<year>2025</year>) <volume>35</volume>:<fpage>67</fpage>&#x2013;<lpage>86</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.semradonc.2024.10.003</pub-id>, PMID: <pub-id pub-id-type="pmid">39672644</pub-id>
</mixed-citation>
</ref>
<ref id="B3">
<label>3</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hoseinnezhad Zarghani</surname> <given-names>E</given-names></name>
<name><surname>Geraily</surname> <given-names>G</given-names></name>
<name><surname>Haddad</surname> <given-names>P</given-names></name>
<name><surname>Esfahani</surname> <given-names>M</given-names></name>
<name><surname>Farzin</surname> <given-names>M</given-names></name>
<name><surname>Rastjoo</surname> <given-names>A</given-names></name>
<etal/>
</person-group>. 
<article-title>Dosimetric comparison of AP/PA and bilateral geometries for total body irradiation treatment</article-title>. <source>Radiat Environ Biophys</source>. (<year>2021</year>) <volume>60</volume>:<page-range>663&#x2013;72</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00411-021-00933-7</pub-id>, PMID: <pub-id pub-id-type="pmid">34487229</pub-id>
</mixed-citation>
</ref>
<ref id="B4">
<label>4</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Alvero&#x11f;lu</surname> <given-names>GU</given-names></name>
<name><surname>&#xc7;eltik</surname> <given-names>&#x130;K</given-names></name>
<name><surname>Akba&#x15f;</surname> <given-names>CK</given-names></name>
<name><surname>Becerir</surname> <given-names>HB</given-names></name>
</person-group>. 
<article-title>Dosimetric evaluation of total body irradiations with helical tomotherapy: phantom study</article-title>. <source>Turk J Oncol</source>. (<year>2022</year>) <volume>38</volume>:<page-range>104&#x2013;11</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.5505/tjo.2022.3722</pub-id>
</mixed-citation>
</ref>
<ref id="B5">
<label>5</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>K&#xf6;ksal</surname> <given-names>M</given-names></name>
<name><surname>Baumert</surname> <given-names>J</given-names></name>
<name><surname>Jazmati</surname> <given-names>D</given-names></name>
<name><surname>Schoroth</surname> <given-names>F</given-names></name>
<name><surname>Garbe</surname> <given-names>S</given-names></name>
<name><surname>Koch</surname> <given-names>D</given-names></name>
<etal/>
</person-group>. 
<article-title>Whole body irradiation with intensity-modulated helical tomotherapy prior to haematopoietic stem cell transplantation: analysis of organs at risk by dose and its effect on blood kinetics</article-title>. <source>J Cancer Res Clin Oncol</source>. (<year>2023</year>) <volume>149</volume>:<page-range>7007&#x2013;15</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00432-023-04657-7</pub-id>, PMID: <pub-id pub-id-type="pmid">36856852</pub-id>
</mixed-citation>
</ref>
<ref id="B6">
<label>6</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Seravalli</surname> <given-names>E</given-names></name>
<name><surname>Bosman</surname> <given-names>ME</given-names></name>
<name><surname>Han</surname> <given-names>C</given-names></name>
<name><surname>Losert</surname> <given-names>C</given-names></name>
<name><surname>Pazos</surname> <given-names>M</given-names></name>
<name><surname>Engstr&#xf6;m</surname> <given-names>PE</given-names></name>
<etal/>
</person-group>. 
<article-title>Technical recommendations for implementation of Volumetric Modulated Arc Therapy and Helical Tomotherapy Total Body Irradiation</article-title>. <source>Radiother Oncol</source>. (<year>2024</year>) <volume>197</volume>:<elocation-id>110366</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.radonc.2024.110366</pub-id>, PMID: <pub-id pub-id-type="pmid">38830537</pub-id>
</mixed-citation>
</ref>
<ref id="B7">
<label>7</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Nozawa</surname> <given-names>Y</given-names></name>
<name><surname>Yamashita</surname> <given-names>H</given-names></name>
<name><surname>Sawayanagi</surname> <given-names>S</given-names></name>
<name><surname>Katano</surname> <given-names>A</given-names></name>
</person-group>. 
<article-title>First clinical experience of total body irradiation using volumetric modulated arc therapy technique in Japan</article-title>. <source>J Cancer Res Ther</source>. (<year>2025</year>) <volume>21</volume>:<page-range>237&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4103/jcrt.jcrt_1067_23</pub-id>, PMID: <pub-id pub-id-type="pmid">39207090</pub-id>
</mixed-citation>
</ref>
<ref id="B8">
<label>8</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Milgrom</surname> <given-names>SA</given-names></name>
<name><surname>Dandapani</surname> <given-names>SV</given-names></name>
<name><surname>Wong</surname> <given-names>J</given-names></name>
<name><surname>Kalapurakal</surname> <given-names>J</given-names></name>
<name><surname>Smith</surname> <given-names>KS</given-names></name>
<name><surname>Han</surname> <given-names>C</given-names></name>
<etal/>
</person-group>. 
<article-title>Incorporating intensity modulated total body irradiation into a Children&#x2019;s Oncology Group trial: Rationale, techniques, and safeguards</article-title>. <source>Pediatr Blood Cancer</source>. (<year>2024</year>) <volume>71</volume>:<elocation-id>e31185</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/pbc.31185</pub-id>, PMID: <pub-id pub-id-type="pmid">39118225</pub-id>
</mixed-citation>
</ref>
<ref id="B9">
<label>9</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hui</surname> <given-names>C</given-names></name>
<name><surname>Simiele</surname> <given-names>E</given-names></name>
<name><surname>Lozko</surname> <given-names>Y</given-names></name>
<name><surname>Romero</surname> <given-names>I</given-names></name>
<name><surname>Skinner</surname> <given-names>L</given-names></name>
<name><surname>Binkley</surname> <given-names>MS</given-names></name>
<etal/>
</person-group>. 
<article-title>Volumetric modulated arc therapy total body irradiation improves toxicity outcomes compared to 2D total body irradiation</article-title>. <source>Front Oncol</source>. (<year>2024</year>) <volume>14</volume>:<elocation-id>1459287</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2024.1459287</pub-id>, PMID: <pub-id pub-id-type="pmid">39351359</pub-id>
</mixed-citation>
</ref>
<ref id="B10">
<label>10</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gao</surname> <given-names>B</given-names></name>
<name><surname>Yao</surname> <given-names>Z</given-names></name>
<name><surname>Wu</surname> <given-names>L</given-names></name>
<name><surname>Shao</surname> <given-names>K</given-names></name>
<name><surname>Lin</surname> <given-names>X</given-names></name>
<name><surname>Liang</surname> <given-names>Q</given-names></name>
<etal/>
</person-group>. 
<article-title>Necessity of daily IGRT? Dosimetric study of beam position offsets at central double-beam junction in pediatric craniospinal irradiation</article-title>. <source>BMC Cancer</source>. (<year>2025</year>) <volume>26</volume>:<elocation-id>4</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12885-025-15388-y</pub-id>, PMID: <pub-id pub-id-type="pmid">41316040</pub-id>
</mixed-citation>
</ref>
<ref id="B11">
<label>11</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Son</surname> <given-names>K</given-names></name>
<name><surname>Kim</surname> <given-names>JS</given-names></name>
<name><surname>Lee</surname> <given-names>H</given-names></name>
<name><surname>Cho</surname> <given-names>S</given-names></name>
</person-group>. 
<article-title>Imaging dose of human organs from kv-cbct in image-guided radiation therapy</article-title>. <source>Radiat Prot Dosim</source>. (<year>2016</year>) <volume>175</volume>:<page-range>194&#x2013;200</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/rpd/ncw285</pub-id>, PMID: <pub-id pub-id-type="pmid">27765832</pub-id>
</mixed-citation>
</ref>
<ref id="B12">
<label>12</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gong</surname> <given-names>W</given-names></name>
<name><surname>Yao</surname> <given-names>Y</given-names></name>
<name><surname>Ni</surname> <given-names>J</given-names></name>
<name><surname>Jiang</surname> <given-names>H</given-names></name>
<name><surname>Jia</surname> <given-names>L</given-names></name>
<name><surname>Xiong</surname> <given-names>W</given-names></name>
<etal/>
</person-group>. 
<article-title>Deep learning-based low-dose CT for adaptive radiotherapy of abdominal and pelvic tumors</article-title>. <source>Front Oncol</source>. (<year>2022</year>) <volume>12</volume>:<elocation-id>968537</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2022.968537</pub-id>, PMID: <pub-id pub-id-type="pmid">36059630</pub-id>
</mixed-citation>
</ref>
<ref id="B13">
<label>13</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gao</surname> <given-names>RW</given-names></name>
<name><surname>Weisdorf</surname> <given-names>DJ</given-names></name>
<name><surname>DeFor</surname> <given-names>TE</given-names></name>
<name><surname>Ehler</surname> <given-names>E</given-names></name>
<name><surname>Dusenbery</surname> <given-names>KE</given-names></name>
</person-group>. 
<article-title>Influence of total body irradiation dose rate on idiopathic pneumonia syndrome in acute leukemia patients undergoing allogeneic hematopoietic cell transplantation</article-title>. <source>Int J Radiat OncolBiolPhys</source>. (<year>2019</year>) <volume>103</volume>:<page-range>180&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ijrobp.2018.09.002</pub-id>, PMID: <pub-id pub-id-type="pmid">30205123</pub-id>
</mixed-citation>
</ref>
<ref id="B14">
<label>14</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Patel</surname> <given-names>RP</given-names></name>
<name><surname>Warry</surname> <given-names>AJ</given-names></name>
<name><surname>Eaton</surname> <given-names>DJ</given-names></name>
<name><surname>Collis</surname> <given-names>CH</given-names></name>
<name><surname>Rosenberg</surname> <given-names>I</given-names></name>
</person-group>. 
<article-title><italic>In vivo</italic> dosimetry for total body irradiation: five-year results and technique comparison</article-title>. <source>J Appl Clin Med Phys</source>. (<year>2014</year>) <volume>15</volume>:<page-range>306&#x2013;15</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1120/jacmp.v15i4.4939</pub-id>, PMID: <pub-id pub-id-type="pmid">25207423</pub-id>
</mixed-citation>
</ref>
<ref id="B15">
<label>15</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kawa-Iwanicka</surname> <given-names>A</given-names></name>
<name><surname>&#x141;obodziec</surname> <given-names>W</given-names></name>
<name><surname>Dybek</surname> <given-names>M</given-names></name>
<name><surname>Nenko</surname> <given-names>D</given-names></name>
<name><surname>Iwanicki</surname> <given-names>T</given-names></name>
</person-group>. 
<article-title>Dose distribution homogeneity in two TBI techniques&#x2014;Analysis of 208 irradiated patients conducted in Stanislaw Leszczynski Memorial Hospital, Katowice</article-title>. <source>Rep Pract Oncol Radiother</source>. (<year>2012</year>) <volume>17</volume>:<page-range>367&#x2013;75</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.rpor.2012.07.013</pub-id>, PMID: <pub-id pub-id-type="pmid">24377040</pub-id>
</mixed-citation>
</ref>
<ref id="B16">
<label>16</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sarkar</surname> <given-names>B</given-names></name>
<name><surname>Pradhan</surname> <given-names>A</given-names></name>
</person-group>. 
<article-title>Long term <italic>in-vivo</italic> dosimetry result for bilateral oppose extended source to surface distance (SSD) total body irradiation</article-title>. <source>Radiat Phys Chem</source>. (<year>2025</year>) <volume>229</volume>:<elocation-id>112541</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.radphyschem.2025.112541</pub-id>, PMID: <pub-id pub-id-type="pmid">41760527</pub-id>
</mixed-citation>
</ref>
<ref id="B17">
<label>17</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname> <given-names>Q</given-names></name>
<name><surname>Gu</surname> <given-names>W</given-names></name>
<name><surname>Mu</surname> <given-names>J</given-names></name>
<name><surname>Yin</surname> <given-names>W</given-names></name>
<name><surname>Gao</surname> <given-names>M</given-names></name>
<name><surname>Mo</surname> <given-names>J</given-names></name>
<etal/>
</person-group>. 
<article-title>Collimator rotation in volumetric modulated arc therapy for craniospinal irradiation and the dose distribution in the beam junction region</article-title>. <source>Radiat Oncol</source>. (<year>2015</year>) <volume>10</volume>:<elocation-id>235</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13014-015-0544-z</pub-id>, PMID: <pub-id pub-id-type="pmid">26584626</pub-id>
</mixed-citation>
</ref>
<ref id="B18">
<label>18</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhou</surname> <given-names>Y</given-names></name>
<name><surname>Ai</surname> <given-names>Y</given-names></name>
<name><surname>Han</surname> <given-names>C</given-names></name>
<name><surname>Zheng</surname> <given-names>X</given-names></name>
<name><surname>Yi</surname> <given-names>J</given-names></name>
<name><surname>Xie</surname> <given-names>C</given-names></name>
<etal/>
</person-group>. 
<article-title>Impact of setup errors on multi-isocenter volumetric modulated arc therapy for craniospinal irradiation</article-title>. <source>J Appl Clin Med Phys</source>. (<year>2020</year>) <volume>21</volume>:<page-range>115&#x2013;23</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/acm2.13044</pub-id>, PMID: <pub-id pub-id-type="pmid">33070426</pub-id>
</mixed-citation>
</ref>
<ref id="B19">
<label>19</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yu</surname> <given-names>L</given-names></name>
<name><surname>Zhao</surname> <given-names>J</given-names></name>
<name><surname>Zhang</surname> <given-names>Z</given-names></name>
<name><surname>Wang</surname> <given-names>J</given-names></name>
<name><surname>Hu</surname> <given-names>W</given-names></name>
</person-group>. 
<article-title>Commissioning of and preliminary experience with a new fully integrated computed tomography linac</article-title>. <source>J Appl Clin Med Phys</source>. (<year>2021</year>) <volume>22</volume>:<page-range>208&#x2013;23</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/acm2.13313</pub-id>, PMID: <pub-id pub-id-type="pmid">34151504</pub-id>
</mixed-citation>
</ref>
<ref id="B20">
<label>20</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wong</surname> <given-names>JYC</given-names></name>
<name><surname>Filippi</surname> <given-names>AR</given-names></name>
<name><surname>Dabaja</surname> <given-names>BS</given-names></name>
<name><surname>Yahalom</surname> <given-names>J</given-names></name>
<name><surname>Specht</surname> <given-names>L</given-names></name>
</person-group>. 
<article-title>Total body irradiation: guidelines from the international lymphoma radiation oncology group (ILROG)</article-title>. <source>Int J Radiat OncolBiolPhys</source>. (<year>2018</year>) <volume>101</volume>:<page-range>521&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ijrobp.2018.04.071</pub-id>, PMID: <pub-id pub-id-type="pmid">29893272</pub-id>
</mixed-citation>
</ref>
<ref id="B21">
<label>21</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Guo</surname> <given-names>B</given-names></name>
<name><surname>Sheen</surname> <given-names>C</given-names></name>
<name><surname>Murphy</surname> <given-names>E</given-names></name>
<name><surname>Magnelli</surname> <given-names>A</given-names></name>
<name><surname>Lu</surname> <given-names>L</given-names></name>
<name><surname>Cho</surname> <given-names>Y</given-names></name>
<etal/>
</person-group>. 
<article-title>Image-guided volumetric-modulated arc therapy of total body irradiation: An efficient workflow from simulation to delivery</article-title>. <source>J Appl Clin Med Phys</source>. (<year>2021</year>) <volume>22</volume>:<page-range>169&#x2013;77</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/acm2.13412</pub-id>, PMID: <pub-id pub-id-type="pmid">34480829</pub-id>
</mixed-citation>
</ref>
<ref id="B22">
<label>22</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kal</surname> <given-names>HB</given-names></name>
<name><surname>van Kempen-Harteveld</surname> <given-names>ML</given-names></name>
</person-group>. 
<article-title>Renal dysfunction after total body irradiation: Dose&#x2013;effect relationship</article-title>. <source>Int J Radiat OncolBiolPhys</source>. (<year>2006</year>) <volume>65</volume>:<page-range>1228&#x2013;32</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ijrobp.2006.02.021</pub-id>, PMID: <pub-id pub-id-type="pmid">16682132</pub-id>
</mixed-citation>
</ref>
<ref id="B23">
<label>23</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Shahid</surname> <given-names>T</given-names></name>
<name><surname>Mandal</surname> <given-names>S</given-names></name>
<name><surname>Biswal</surname> <given-names>SS</given-names></name>
<name><surname>De</surname> <given-names>A</given-names></name>
<name><surname>Mukherjee</surname> <given-names>M</given-names></name>
<name><surname>Roy Chowdhury</surname> <given-names>S</given-names></name>
<etal/>
</person-group>. 
<article-title>Preclinical validation and treatment of volumetric modulated arc therapy based total bone marrow irradiation in HalcyonTM ring gantry linear accelerator</article-title>. <source>Radiat Oncol</source>. (<year>2022</year>) <volume>17</volume>:<elocation-id>145</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13014-022-02109-z</pub-id>, PMID: <pub-id pub-id-type="pmid">35986327</pub-id>
</mixed-citation>
</ref>
</ref-list>
<fn-group>
<fn id="n1" fn-type="custom" custom-type="edited-by">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1400806">Haibo Lin</ext-link>, New York Proton Center, United States</p></fn>
<fn id="n2" fn-type="custom" custom-type="reviewed-by">
<p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2842679">Elahheh Salari</ext-link>, Emory University, United States</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3329954">Subhrasnigdha Biswal</ext-link>, Apollo Gleneagles Hospitals, India</p></fn>
</fn-group>
</back>
</article>